We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
Read MoreHide Full Article
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. (HALO - Free Report) entered into a collaboration and license agreement that gives the former exclusive access to the latter’s ENHANZE drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R.
Shares of Horizon have surged 93.5% year to date while the industry did not show any movement.
Horizon plans to use ENHANZE to develop an SC formulation of its lead drug, Tepezza (teprotumumab-trbw), which is indicated for the treatment of Thyroid Eye Disease, which is a serious, progressive and vision-threatening rare autoimmune disease. The company wishes to provide greater flexibility to patients and physicians and thus, wants to bring out an SC version of Tepezza.
Per the agreement, Horizon will make an upfront payment of $30 million to Halozyme and will have to make potential future payments of up to $160 million in aggregate. The future payments will be,subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also be entitled to receive mid-single-digit royalties on sales of commercialized medicines using the ENHANZE technology.
This is Horizon’s tenth collaboration and license agreement for the ENHANZE technology.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Shares of the company have decreased 37.5% year to date.
Abeona’s loss per share estimates have narrowed from 96 cents to 88 cents for 2020 and from 69 cents to 64 cents for 2021 over the past 60 days. Shares of the company have decreased 52% year to date.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology
Horizon Therapeutics plc and Halozyme Therapeutics, Inc. (HALO - Free Report) entered into a collaboration and license agreement that gives the former exclusive access to the latter’s ENHANZE drug delivery technology for subcutaneous (SC) formulation of medicines targeting IGF-1R.
Shares of Horizon have surged 93.5% year to date while the industry did not show any movement.
Horizon plans to use ENHANZE to develop an SC formulation of its lead drug, Tepezza (teprotumumab-trbw), which is indicated for the treatment of Thyroid Eye Disease, which is a serious, progressive and vision-threatening rare autoimmune disease. The company wishes to provide greater flexibility to patients and physicians and thus, wants to bring out an SC version of Tepezza.
Per the agreement, Horizon will make an upfront payment of $30 million to Halozyme and will have to make potential future payments of up to $160 million in aggregate. The future payments will be,subject to achievement of specified development, regulatory and sales-based milestones. Halozyme will also be entitled to receive mid-single-digit royalties on sales of commercialized medicines using the ENHANZE technology.
This is Horizon’s tenth collaboration and license agreement for the ENHANZE technology.
Horizon Therapeutics Public Limited Company Price
Horizon Therapeutics Public Limited Company price | Horizon Therapeutics Public Limited Company Quote
Zacks Rank & Stocks to Consider
Horizon currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector include ASLAN Pharmaceuticals Ltd. (ASLN - Free Report) and Abeona Therapeutics Inc. ,both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ASLAN’s loss per share estimates have narrowed from 42 cents to 40 cents for 2020 and from 60 cents to 57 cents for 2021 over the past 60 days. Shares of the company have decreased 37.5% year to date.
Abeona’s loss per share estimates have narrowed from 96 cents to 88 cents for 2020 and from 69 cents to 64 cents for 2021 over the past 60 days. Shares of the company have decreased 52% year to date.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>